According to the latest market intelligence report by BIS Research titled, ‘Global Cell-Free DNA Isolation and Extraction Market- Analysis and Forecasts (2018-2026)’, North America is the leading contributor to the market, in terms of both, volume and revenue. The advancements in the cell-free DNA testing have paved the way for the development of multiple advanced technologies to provide aid against genetic and infectious diseases. Among the application segment, non-invasive prenatal testing (NIPT) held the largest market share for cfDNA isolation and extraction market, in the year 2016.
In March 2018, QIAGEN, a world leader in the sample- to- insight molecular solutions, and Natera Inc., a leading developer of Next Generation Sequencing assays, developed cutting-edge cell-free DNA assays. The cell-free DNA assays are developed to use the Gene Reader NGS system and are also used for prenatal screening in hospitals and laboratories, globally. The assays developed by the companies, provide significant clinical and economical values supported by the extensive validation data and large clinical studies.1
In February 2018, Becton, Dickinson and Company (B&D), a leading global medical technology company, launched a circulating cell-free DNA blood collection tube. The tube is specifically designed for cancer and non-invasive prenatal testing applications. The plastic blood collection tube, is designed to ensure correct and reproducible results in molecular diagnostic applications using circulation cell-free DNA(cfDNA). Molecular diagnostic tests using cfDNA enable clinicians to gain actionable biological insights without the use of tissue biopsy or similar invasive tests.2
In February 2018, Thermo Fisher Scientific, the world leader in serving science, developed a cell-free extraction device. The device offers a complete sample to knowledge workflow for next-generation sequencing(NGS), reverse transcription polymerase chain reaction (RT-PCR), and capillary electrophoresis (CE) sequencing applications. Thermo Fisher introduced the automation device to streamline workflows, optimize productivity, and to increase the result time.3
According to BIS Healthcare, companies in the cell-free DNA isolation and extraction market are working on the development of cfDNA isolation/extraction kits and automated instruments on various sequencing platforms. NGS and PCR are the sequencing platforms expected to raise the demands for non-invasive screening tests and procedures. Agilent Technologies Inc., Berry Genomics, BGI Diagnostics, GATC Biotech AG, Illumina Inc., Laboratory Corporation of America, Life Codexx AG, and Bio Scientific Corporation, among others are the significant contributors to the global market for cell-free DNA isolation and extraction.
References:
